Spruce Street Capital LP Invests $12.26 Million in Dianthus Therapeutics, Inc. $DNTH

Spruce Street Capital LP bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 4th quarter, HoldingsChannel reports. The fund bought 297,437 shares of the company’s stock, valued at approximately $12,257,000. Dianthus Therapeutics makes up approximately 4.0% of Spruce Street Capital LP’s portfolio, making the stock its 10th largest holding.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth approximately $40,000. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics in the second quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new position in shares of Dianthus Therapeutics in the third quarter worth approximately $64,000. Quarry LP bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth approximately $99,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth approximately $135,000. Institutional investors own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

DNTH has been the topic of several analyst reports. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Truist Financial upped their target price on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Oppenheimer upped their target price on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research note on Monday, March 9th. Finally, Wells Fargo & Company initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.82.

Insider Buying and Selling

In related news, EVP Ryan Savitz sold 114,367 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total transaction of $9,492,461.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the transaction, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 149,121 shares of company stock worth $12,635,454. 3.02% of the stock is owned by insiders.

Dianthus Therapeutics Stock Up 0.5%

Shares of Dianthus Therapeutics stock opened at $82.51 on Tuesday. The company has a market cap of $4.51 billion, a price-to-earnings ratio of -19.98 and a beta of 1.18. The company’s 50 day moving average is $87.03 and its 200 day moving average is $65.49. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.